Cyclophosphamide and Bortezomib in Preventing Graft Versus Host Disease in Patients with Hematological Malignancies after Blood Stem Cell Transplant

Inclusion Criteria

• Patients with hematological malignancies undergoing an allogeneic transplant with a fludarabine, busulfan, and rATG conditioning regimen, using an eligible or suitable >= 8 out of 8 match (high resolution match at loci A, B, C, and DRB1) related or unrelated donor are eligible to participate
• Karnofsky score >= 70%
• No evidence of progressive bacterial, viral, or fungal infection
• Creatinine clearance > 50 mL/min/1.72 m^2
• Total bilirubin < 2 x the upper limit of normal (except for Gilbert’s syndrome)
• Alanine aminotransferase (ALT) < 2 x the upper limit of normal (except for Gilbert’s syndrome)
• Aspartate aminotransferase (AST) < 2 x the upper limit of normal (except for Gilbert’s syndrome)
• Alkaline phosphatase =< 250 IU/L
• Left ventricular ejection fraction (LVEF) > 45%
• Adjusted carbon monoxide diffusing capacity (DLCO) > 60%
• Negative human immunodeficiency virus (HIV) serology
• Negative pregnancy test: confirmation per negative serum beta-human chorionic gonadotropin (beta-hCG)

Exclusion Criteria

• Donors are excluded in case of donor-specific human leukocyte antigen (HLA) antibodies or positive cross-matching
• Pregnant or nursing females or women of reproductive capability who are unwilling to completely abstain from heterosexual sex or practice 2 effective methods of contraception from the first dose of bortezomib through 90 days after the last dose. A woman of reproductive capability is one who has not undergone a hysterectomy (removal of the womb), has not had both ovaries removed, or has not been post-menopausal (stopped menstrual periods) for more than 24 months in a row
• Male subjects who refuse to practice effective barrier contraception during the entire study treatment period and through a minimum of 90 days after the last dose of study drug, or completely abstain from heterosexual intercourse. This must be done even if they are surgically sterilized (i.e., post-vasectomy)
• Inability to provide informed consent
• Patient had myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) class III or IV heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any electrocardiogram (ECG) abnormality at screening must be documented by the investigator as not medically relevant
• Known allergies to any of the components of the investigational treatment regimen
• Serious medical or psychiatric illness likely to interfere with participation in this clinical study
• Diagnosed or treated for another malignancy within 3 years of enrollment, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma, an in-situ malignancy, or low-risk prostate cancer after curative therapy
• Participation in clinical trials with other investigational agents not included in this trial, within 14 days of the start of this trial and throughout the duration of this trial
• Prisoners